---
title: "D. Western Therapeutics Gains FDA Approval for Bondlido Patch"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/258777157.md"
description: "D. Western Therapeutics Institute has received FDA approval for its Bondlido lidocaine patch, aimed at treating post-herpetic neuralgia in adults. The product is set to launch in the US in early 2026, potentially enhancing the company's earnings in the $162 million US lidocaine patch market. Currently, analysts rate the stock (JP:4576) as a Sell with a price target of Yen102.00. The company focuses on innovative drug development, collaborating with firms like MEDRx."
datetime: "2025-09-25T00:22:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258777157.md)
  - [en](https://longbridge.com/en/news/258777157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258777157.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/258777157.md) | [繁體中文](https://longbridge.com/zh-HK/news/258777157.md)


# D. Western Therapeutics Gains FDA Approval for Bondlido Patch

The latest announcement is out from D.Western Therapeutics Institute ( (JP:4576) ).

D. Western Therapeutics Institute, Inc. has received FDA approval for its new product, Bondlido, a lidocaine patch developed with MEDRx for treating post-herpetic neuralgia in adults. The product is expected to launch in the US in the first half of 2026, potentially improving the company’s earnings over the medium to long term by offering a superior alternative to existing products in the $162 million US lidocaine patch market.

The most recent analyst rating on (JP:4576) stock is a Sell with a Yen102.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.

**More about D.Western Therapeutics Institute**

D. Western Therapeutics Institute, Inc. operates in the pharmaceutical industry, focusing on the development of therapeutic products. The company is known for its innovative approaches in drug development, particularly in collaboration with other firms, such as MEDRx, to enhance treatment options in the market.

**Average Trading Volume:** 1,156,304

**Technical Sentiment Signal:** Sell

**Current Market Cap:** Yen5.43B

For an in-depth examination of 4576 stock, go to TipRanks’ Overview page.

## 相关资讯与研究

- [$100 Invested In ProShares Ultra Silver 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/zh-CN/news/281548227.md)
- [Why Is Silver Down 4% Today, 4/2/26?](https://longbridge.com/zh-CN/news/281547191.md)
- [Iridium Communications Stock (IRDM) Moonshots 12% on SpaceX IPO Filing and Amazon Takeover Rumors](https://longbridge.com/zh-CN/news/281548482.md)
- [What Zhipu and MiniMax’s first post-IPO earnings say about the 2 AI start-ups](https://longbridge.com/zh-CN/news/281474299.md)
- [Trump speech unleashes more pain on US consumers with $5 gasoline, record diesel in sight](https://longbridge.com/zh-CN/news/281550771.md)